Further, given consideration that the circadian clock plays a crucial role in a variety of human diseases including inflammation, metabolism, and cancer [12,28,29] and BMAL1 is a core circadian protein [4], the BMAL1-PAS-domain may become a promising pharmacological target to control not only inflammation but also many circadian-related human disorders. This evidence concerns the gene CLOCK and cancer.